Not to say that it's always the case, but research isn't always at face value - i.e., sometimes there's circularity, economical or political dynamics, etc, that perpetuate dead ends while neglecting more viable avenues.
An example might be enzymes (notably in cancer research), where in the US there has been significantly less pursuit than elsewhere. To avoid attacks, I'll cite a source[0] which readers can maim rather than my comment.
0. Enzymes, The Fountain of Life
DA, Lopez MD
RM, Williams MD PhD
K, Miehlke MD
In some pirtions of this book, entities other than pinata boy on HN, express concern regarding the quality, fairness or whatever's of research, with indications that 'research' may not always be equally noble or pragmatically guided. I suspect it's one of many where that particular subject is grazed upon. But my point is, if not overemphasized, that there may be quantity over quality issues, with viable options hiding in plain sight.
An example might be enzymes (notably in cancer research), where in the US there has been significantly less pursuit than elsewhere. To avoid attacks, I'll cite a source[0] which readers can maim rather than my comment.
0. Enzymes, The Fountain of Life DA, Lopez MD RM, Williams MD PhD K, Miehlke MD
In some pirtions of this book, entities other than pinata boy on HN, express concern regarding the quality, fairness or whatever's of research, with indications that 'research' may not always be equally noble or pragmatically guided. I suspect it's one of many where that particular subject is grazed upon. But my point is, if not overemphasized, that there may be quantity over quality issues, with viable options hiding in plain sight.